Welcome to our dedicated page for Uniqure SEC filings (Ticker: QURE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The uniQure N.V. (QURE) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission. As a Nasdaq Global Select Market issuer, uniQure files current reports on Form 8‑K, annual reports on Form 10‑K, and quarterly reports on Form 10‑Q that describe its gene therapy business, clinical programs, financial condition, and material agreements. These filings document the company’s work in hemophilia B, Huntington’s disease, refractory temporal lobe epilepsy, ALS, Fabry disease, and other severe conditions.
For uniQure, Form 8‑K filings are particularly important. They include clinical and regulatory updates on AMT‑130 for Huntington’s disease, such as topline Phase I/II data, details of pivotal trial design, and feedback from pre‑Biologics License Application meetings with the U.S. Food and Drug Administration. Other 8‑K reports describe public offerings of ordinary shares and pre‑funded warrants, amendments to senior secured term loan facilities with Hercules Capital, and the establishment of at‑the‑market equity programs. Filings also reference the company’s role in the multi‑year clinical development of a gene therapy for hemophilia B and its licensing arrangements with CSL.
On this page, investors can review uniQure’s SEC documents to understand how it reports results of operations, research and development spending, direct financial obligations, and other events that may affect QURE stock. Stock Titan enhances access to these filings with AI‑powered summaries that highlight key points from lengthy reports, helping readers quickly identify major clinical milestones, regulatory decisions, financing terms, and risk disclosures. Real‑time updates from EDGAR, along with structured access to items such as 8‑K current reports and other registered offerings, support deeper analysis of uniQure’s evolving gene therapy portfolio and capital structure.
uniQure N.V. (QURE): Nantahala and its principals report a 3.75% beneficial stake. As of June 30, 2025, Nantahala Capital Management, LLC and its managing members, Wilmot B. Harkey and Daniel Mack, may be deemed beneficial owners of 2,051,852 ordinary shares, representing 3.75% of the outstanding class. The filing states that all reported shares are held by funds and separately managed accounts under Nantahala's control and that the Reporting Persons have shared voting and shared dispositive power over those shares, with no sole voting or dispositive power reported. The filing is made under Schedule 13G classification for an investment adviser and indicates the position is held in the ordinary course of business and not for the purpose of changing control.
Vestal Point Capital, LP and Ryan Wilder reported beneficial ownership of 3,700,000 ordinary shares of uniQure N.V., representing 6.8% of the outstanding class. The shares are directly held by a Vestal Point-managed fund and a managed account; Mr. Wilder is the Chief Investment Officer and managing partner of the investment manager and reports shared voting and dispositive power over the shares. The percent calculation uses 54,748,496 ordinary shares outstanding as of May 6, 2025. The filing states the holdings were acquired in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
RTW Investments, LP and Roderick Wong report a passive 9.4% stake in uniQure (QURE), holding 5,158,231 ordinary shares. The holdings are held directly by the RTW Funds and RTW Investments and Dr. Wong report shared voting and dispositive power over all 5,158,231 shares and report no sole voting or dispositive power. The percentage is calculated using 54,865,673 shares outstanding as reported for the period cited in the filing. The statement is made on a Schedule 13G basis and includes a certification that the shares were acquired and are held in the ordinary course of business and not to change or influence control of the issuer.
Avoro Capital Advisors LLC and Behzad Aghazadeh report holding 3,625,000 ordinary shares of uniQure N.V., representing 6.6% of the outstanding class. The percentage is calculated using 54,748,496 ordinary shares outstanding as of May 6, 2025. The filing states the shares were acquired and are held for investment purposes on behalf of Avoro Life Sciences Fund LLC, and that the reporting persons have sole voting and sole dispositive power over the reported shares. The statement also notes the filing should not be construed as an admission of beneficial ownership for Section 13 purposes. Avoro Life Sciences Fund LLC is identified as having the right to receive dividends or sale proceeds for the position.
Aberdeen Group plc and subsidiary abrdn Inc. have filed a Schedule 13G disclosing a new passive position in uniQure N.V. (QURE).
- Shares owned: 2,750,714 ordinary shares
- Ownership: 5.02 % of the outstanding class
- Voting/Dispositive power: 0 sole / 2,750,714 shared
- Event date: 30 Jun 2025 | Filing signed: 30 Jul 2025
- SEC classifications: Aberdeen – Parent Holding Company (HC); abrdn Inc. – Investment Adviser & Corporation (IA, CO)
- Certification affirms the stake was acquired in the ordinary course and not intended to influence control.
The filing adds a sizeable institutional holder to uniQure’s share register, but because it is a 13G (passive) submission, it carries no stated activist intent.
uniQure N.V. (QURE) announced an at-the-market (ATM) equity offering program via Form 8-K. Under a new Sales Agreement dated 29 Jul 2025, Leerink Partners LLC will act as sales agent to place up to $200 million of ordinary shares (€0.05 par value) from time to time. Sales may occur on Nasdaq, other U.S. trading venues or through negotiated transactions, and will be executed on a “commercially reasonable efforts” basis.
Key terms:
- Commission: up to 3.0% of gross proceeds to Leerink Partners.
- No obligation: uniQure can choose whether, when and how much stock to sell; the agreement terminates after all shares are sold or upon earlier termination by the parties.
- Registration: shares will be issued under the company’s effective shelf registration statement (Form S-3ASR, File No. 333-284168).
- Legal opinions & exhibits: Sales Agreement (Ex. 1.1), legal opinion (Ex. 5.1) and related consents filed.
The facility enhances capital-raising flexibility but may dilute existing shareholders if fully utilized. No immediate share issuance or financial impact is disclosed.
uniQure N.V. (QURE) filed a prospectus supplement for an “at-the-market” equity program of up to $200 million in ordinary shares, par €0.05, to be sold from time to time through Leerink Partners LLC.
Leerink will act as sales agent and is entitled to a commission of up to 3 % of gross proceeds and will be treated as an underwriter. Shares will be issued on The Nasdaq Global Select Market at prevailing prices. Using the 25-Jul-2025 close of $15.11, a full draw would add roughly 13.24 m shares, lifting total shares outstanding to 68.10 m.
- Post-offering pro-forma net tangible book value rises from −$2.08 to $1.17 per share, creating immediate dilution of $13.94 for new investors.
- Proceeds will fund the potential U.S. launch of lead gene-therapy AMT-130, advance multiple clinical programs (AMT-260, AMT-191, AMT-162), support business development and general corporate needs.
- Risk highlights: discretionary use of funds, potential share-price pressure from sales, extensive outstanding equity awards, PFIC classification for 2024, no dividend policy and share-price volatility.
There is no minimum sale requirement and proceeds are not escrowed, giving the company flexibility but leaving investors uncertain about timing and pricing of dilution.
FAQ
What is the current stock price of Uniqure (QURE)?
What is the market cap of Uniqure (QURE)?
